diuretics	reduce	fluid overload
potassium‑sparing agents	prevent	hypokalemia
diuretics	increase	urine output
potassium‑sparing agents	increase	serum potassium
diuretics	cause	electrolyte imbalance
potassium‑sparing agents	cause	hyperkalemia
diuretics	used for	hypertension
potassium‑sparing agents	used for	heart failure
diuretics	include	loop diuretics
diuretics	include	thiazide diuretics
potassium‑sparing agents	include	spironolactone
potassium‑sparing agents	include	amiloride
loop diuretics	act on	Na⁺/K⁺/2Cl⁻ cotransporter
thiazide diuretics	act on	Na⁺/Cl⁻ cotransporter
spironolactone	is an	aldosterone antagonist
amiloride	blocks	ENaC
diuretics	increase	blood pressure variability
potassium‑sparing agents	reduce	diuretic‑induced potassium loss
diuretics	cause	dehydration
potassium‑sparing agents	reduce	renal potassium excretion
diuretics	improve	edema resolution
potassium‑sparing agents	improve	cardiac remodeling
diuretics	increase	risk of gout
potassium‑sparing agents	increase	risk of arrhythmia
diuretics	require	monitoring of electrolytes
potassium‑sparing agents	require	monitoring of potassium
diuretics	can cause	hyponatremia
potassium‑sparing agents	can cause	hyperkalemia
diuretics	are contraindicated in	severe renal failure
potassium‑sparing agents	are contraindicated in	hyperkalemia
diuretics	are contraindicated in	pregnancy (certain types)
potassium‑sparing agents	are contraindicated in	pregnancy (spironolactone)
diuretics	are used in	acute pulmonary edema
potassium‑sparing agents	are used in	chronic kidney disease
diuretics	are used in	nephrotic syndrome
potassium‑sparing agents	are used in	ascites
diuretics	are combined with	ACE inhibitors
potassium‑sparing agents	are combined with	ARBs
diuretics	are combined with	beta‑blockers
potassium‑sparing agents	are combined with	calcium channel blockers
diuretics	are combined with	statins
potassium‑sparing agents	are combined with	digoxin
diuretics	are combined with	anticoagulants
potassium‑sparing agents	are combined with	NSAIDs
diuretics	are combined with	dipeptidyl peptidase‑4 inhibitors
potassium‑sparing agents	are combined with	SGLT2 inhibitors
diuretics	improve	renal perfusion
potassium‑sparing agents	improve	myocardial function
diuretics	reduce	left ventricular hypertrophy
potassium‑sparing agents	reduce	ventricular arrhythmias
diuretics	reduce	mortality in heart failure
potassium‑sparing agents	reduce	mortality in heart failure
diuretics	increase	risk of falls
potassium‑sparing agents	increase	risk of constipation
diuretics	increase	risk of phototoxicity
potassium‑sparing agents	increase	risk of gynecomastia
diuretics	are metabolized by	liver
potassium‑sparing agents	are metabolized by	liver
diuretics	excreted by	kidneys
potassium‑sparing agents	excreted by	kidneys
diuretics	have	half‑life 1–6 hours
potassium‑sparing agents	have	half‑life 20–40 hours
diuretics	are prescribed in	dosage ranges
potassium‑sparing agents	are prescribed in	dosage ranges
diuretics	cause	orthostatic hypotension
potassium‑sparing agents	cause	hyperkalemia‑related ECG changes
diuretics	are monitored by	serum creatinine
potassium‑sparing agents	are monitored by	serum potassium
diuretics	are monitored by	blood pressure
potassium‑sparing agents	are monitored by	blood pressure
diuretics	are associated with	increased uric acid
potassium‑sparing agents	are associated with	decreased uric acid
diuretics	are associated with	metabolic alkalosis
potassium‑sparing agents	are associated with	metabolic acidosis
diuretics	are associated with	increased glucose
potassium‑sparing agents	are associated with	decreased glucose
diuretics	are associated with	increased LDL
potassium‑sparing agents	are associated with	decreased LDL
diuretics	are associated with	increased risk of fractures
potassium‑sparing agents	are associated with	decreased risk of fractures
diuretics	are associated with	increased risk of kidney stones
potassium‑sparing agents	are associated with	decreased risk of kidney stones
diuretics	are associated with	increased risk of anemia
potassium‑sparing agents	are associated with	decreased risk of anemia
diuretics	are associated with	increased risk of cognitive decline
potassium‑sparing agents	are associated with	decreased risk of cognitive decline
diuretics	are associated with	increased risk of depression
potassium‑sparing agents	are associated with	decreased risk of depression
diuretics	are associated with	increased risk of osteoporosis
potassium‑sparing agents	are associated with	decreased risk of osteoporosis
diuretics	are associated with	increased risk of urinary tract infections
potassium‑sparing agents	are associated with	decreased risk of urinary tract infections
diuretics	are associated with	increased risk of hyperuricemia
potassium‑sparing agents	are associated with	decreased risk of hyperuricemia
diuretics	are associated with	increased risk of hyperglycemia
potassium‑sparing agents	are associated with	decreased risk of hyperglycemia
diuretics	are associated with	increased risk of hyperlipidemia
potassium‑sparing agents	are associated with	decreased risk of hyperlipidemia
diuretics	are associated with	increased risk of renal failure
potassium‑sparing agents	are associated with	decreased risk of renal failure
